Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Scientists at Johns Hopkins University have developed an Antibody-Drug Conjugate (ADC) that targets T-cell malignancies, showing effectiveness in vitro and in mouse models. The ADC treatment kills cancerous T cells more selectively than noncancerous ones. The ADC space involves over 160 key players, with detailed profiles of 13 public and private companies available in a report.
Cancer Drugs (Antibody Drug Conjugates): An FDA Perspective https://t.co/jV2Ef657mW #cancer #cancertreatment #health @FoleyandLardner https://t.co/trPCiJrXs6
Antibody-Drug Conjugate Slays Cancerous T Cells, Spares Many Normal T Cells Scientists based at @JohnsHopkins have developed an antibody-drug conjugate (ADC). Their ADC treatment has been shown to be effective in vitro and in mouse models. Learn more: https://t.co/r8MdYLLw6w
#AntibodyDrugConjugate Slays Cancerous T Cells, Spares Many Normal T Cells 👇 @GENbio discusses how an #ADC kills cancerous T cells more zealously than it kills noncancerous T cells. Read the article below 🔗 https://t.co/IboIOt4Wgj
